ArticleOncotarget2017
RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Identification and validation of hub genes involved in papillary thyroid carcinoma progression.BMC cancer · 2026Article
- A novel prognostic model for papillary thyroid cancer based on epithelial-mesenchymal transition-related genes.Cancer medicine · 2022Article
- Article
- LncmiRHG-MIR100HG: A new budding star in cancer.Frontiers in oncology · 2022Review
- Identification of key biomarkers for thyroid cancer by integrative gene expression profiles.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Long Non-coding RNA RUNDC3A-AS1 Promotes Lung Metastasis of Thyroid Cancer via Targeting the miR-182-5p/ADAM9.Frontiers in cell and developmental biology · 2021Article
- Noncoding RNAs in Papillary Thyroid Cancer: Interaction with Cancer-Associated Fibroblasts (CAFs) in the Tumor Microenvironment (TME) and Regulators of Differentiation and Lymph Node Metastasis.Advances in experimental medicine and biology · 2021Article
- Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential.Frontiers in oncology · 2021Article
- Identification of Potential lncRNAs and miRNAs as Diagnostic Biomarkers for Papillary Thyroid Carcinoma Based on Machine Learning.International journal of endocrinology · 2021Article
- Knockdown ofCancer management and research · 2020Article
- Prognostic Value of Long Noncoding RNA CRNDE as a Novel Biomarker in Solid Cancers: An Updated Systematic Review and Meta-Analysis.Journal of Cancer · 2019Article
- Correlations of lncRNAs with cervical lymph node metastasis and prognosis of papillary thyroid carcinoma.OncoTargets and therapy · 2019Article
- LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer.Frontiers in endocrinology · 2019Article
- CRNDE: An important oncogenic long non-coding RNA in human cancers.Cell proliferation · 2018Review
- Development and validation of an individualized diagnostic signature in thyroid cancer.Cancer medicine · 2018Article
- Transcriptome profiling of cancer tissues in Chinese patients with gastric cancer by high-throughput sequencing.Oncology letters · 2018Article
- Molecular Network-Based Identification of Competing Endogenous RNAs in Thyroid Carcinoma.Genes · 2018Article
- Colorectal neoplasia differentially expressed: a long noncoding RNA with an imperative role in cancer.OncoTargets and therapy · 2018Review
- Molecular characterization of papillary thyroid carcinoma: a potential three-lncRNA prognostic signature.Cancer management and research · 2018Article
- Long noncoding RNAOncoTargets and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scholars are striving to apply molecular biology involving long non-coding RNA (lncRNA) in the prognostication of papillary thyroid cancer (PTC). However, the clinical role of lncRNAs in the prognostic setting of PTC is still unclear. Herein, a comprehensive inquiry was performed to screen lncRNA expression profiling with 507 PTC patients from The Cancer Genome Atlas RNA-sequencing datasets. A total of 734 lncRNAs were detected to be aberrantly expressed, among which three novel lncRNAs including AC079630.2, CRNDE and CTD-2171N6.1 were markedly related to the progression and survival of PTC. Furthermore, the aberrant expression of these lncRNAs could be verified by other cohorts from gene expression omnibus (GEO) as detected by microarrays. Next, we established a three-lncRNA signature and divided the PTC patients into two subgroups of high- and low-risk. Interestingly, patients with high-risk tended to gain obviously poorer outcome. Most importantly, this three-lncRNA signature was an independent biomarker to predict the patient survival of PTC. The accurate molecular roles of these three lncRNAs remains unclarified and warrants further characterization, but our current data propose that they might play pivotal roles in PTC tumorigenesis and more importantly, these novel lncRNAs are closely related to patients' survival. These discoveries will have far-reaching consequences with respect to molecular prediction of PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.